MedTrace Logo

A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults

NCT05361434 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 311

Last updated 2026-04-30

No results posted yet for this study

Summary

The purpose of this study is to collect data to describe the safety and effectiveness of cabozantinib and nivolumab in combination as a first-line treatment in adults with aRCC with clear cell-component, according to real-world clinical practice. The decision to prescribe cabozantinib and nivolumab in combination will be made prior to, and independently from, the decision to enrol the participant in study.

Conditions

  • Advanced Renal Cell Carcinoma

Sponsors & Collaborators

Principal Investigators

  • Ipsen Medical Director · Ipsen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-26
Primary Completion
2025-10-20
Completion
2026-11-30

Countries

  • Belgium
  • France
  • Greece
  • Italy
  • Norway
  • Saudi Arabia
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05361434 on ClinicalTrials.gov